Articles On Rhythm Biosciences (ASX:RHY)

ASX healthcare sector gains 1.99% in November while benchmark ASX 200 down 2.66% Mach7 rises 50% in November with health imaging stock outlining a growth strategy at its AGM  Island Pharmaceuticals rises after FDA confirms Galidesivir will...

ASX adds just 14.5 points in subdued day of trade Broad rally in commodity prices lifts resource stocks Crude oil bounces 1.3% as Ukraine continues to strike Russian oil infrastructure   ASX grinds higher on commodity strength A fresh att...

Rhythm transitions geneType Laboratory to ISO 15189:2022 and secures updated accreditation ISO 15189:2022 is the latest international standard for medical laboratories Milestone demonstrates company’s commitment to world-class laboratory s...

RHY’s geneType twice as effective at identifying women with elevated ovarian cancer risk than using clinical or genetic information alone Peer-reviewed study validates Rhythm’s ovarian cancer risk prediction model Cross-validation across t...

ASX healthcare sector fell 4.83% in October and is down more than 19% YTD CSL shares fall more than 15% on October 28 after management trims FY26 guidance Nyrada surges 165% in October on board changes and progress in phase 2a trial    Wi...

Rhythm’s ColoSTAT demonstrates conclusive performance in patients aged 45 to 80 diagnosed with colorectal cancer ColoSTAT performance consistent across both males and females Data indicates potentially suitable for early onset cancer in pa...

October marks Global Breast Cancer Awareness Month with several ASX companies working to advance early detection and treatments for better outcomes Imagion’s first-of-its-kind imaging agent tech MagSense uses targeted nanoparticles to enha...

Tylah Tully chats with Rhythm Biosciences (ASX:RHY) Director of Clinical and Scientific Affairs Dr Erika Spaeth, who explains the growing role of polygenic risk scores (PRS) in preventive healthcare. Dr. Spaeth highlights Rhythm’s GeneType...

The S&P ASX 200 Health Care index fell 13.21% in August as a tough reporting season weighed on sector CSL had its biggest ever one day fall on August 19, down 17% following softer FY25 results and restructure plans Despite the broader...

Tylah Tully chats with Dr Andy Feber, who works in Clinical R&D Translational Oncology and as an external advisor to Rhythm Biosciences (ASX:RHY). Rhythm has just completed the final full system validation of its ColoSTAT, a diagnostic...

Rhythm enters co-marketing deal with geneType to be available on Know Your Lemons mobile app Partnership aligns with Breast Cancer Awareness Month in October, supporting proactive healthcare for women Reaching hundreds of thousands of wome...

ASX slides 0.41pc as full year results disappoint Gold, Small Ords, Tech index enjoy late interest-rate-related rally Consumer staples and Coles soften blow   Coles results plus late gold rally soothes market The ASX spent the vast majori...

Rhythm completes final full system validation of ColoSTAT for the kits, algorithm and instrumentation using range of clinical samples Validation shows simple blood test to detect colon cancer will meet needs for intended clinical indicatio...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am in the east, once trading kicks...

Artrya shares surge up to 42% on FDA clearance of the company’s Salix Coronary Plaque device Sonic Healthcare joins CSL in the healthcare sin bin Universal Biosensors calls in the corporate undertakers   Artrya (ASX:AYA) has won US Food a...

Tylah Tully chats with Rhythm Biosciences (ASX:RHY) CEO and managing director David Atkins about the company’s recently completed $3.75 million placement. Atkins explains that strong demand from both existing and new shareholders allowed Rh...

Rhythm Biosciences to undertake capital raise of up to $3.75 million Proceeds to advance its products including blood test to detect colorectal cancer ColoSTAT progresses toward commercial release following validation of second-generation...

 Pro Medicus shares surge up to 7% on record revenue and earnings Tetratherix pockets $3.3 million, while Rhythm girds for a raising CEO oration inspires Starpharma share run   The $32 billion market cap ProMedicus (ASX:PME) has drawn the...

Bulls N’ Bears ASX Runner of the Week is… Rhythm Biosciences, after the company revealed promising results from a study of its simple bowel cancer diagnostic blood test.

ASX slips just 12.3 points, remaining near all-time high Healthcare leads losses as Trump raises tariff spectre Gains in gold and consumer discretionary soften losses   Profit takers stay their hands When markets hit new closing highs, it...

Gold stocks drive gains with index climbing 3.3pc ASX hits new record close at 8843 points Broad market strength with 10 of 11 sectors up Solid gains supported by gold It was another picturesque day of trading on the ASX today, rising st...

ASX surges 1.23pc on broad strength 11 of 11 sectors positive throughout trade ASX just 0.07pc off all-time high Market powers higher with all cylinders firing The ASX moved to its own tune today, making strong gains in the first hour an...

The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum  Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of Febri...

Highlights ASX closes flat despite a weak global lead Gold explorers and miners post notable gains Tech and financial sectors experience pressure The Australian share market managed to steady itself despite starting th...

ASX ends flat, overcoming difficult trading session Gold stocks lead gains with index up 3.57pc Info tech and financials slide on US market losses   ASX sticks the landing Although all indicators were pointing to a down day on the ASX to...

ColoSTAT diagnostic performance consistent across colorectal cancer I to IV stages Performance meets clinical requirements for symptomatic patient testing use case Commercialisation steps underway as ColoSTAT kit transitioned to final pro...

Imugene and Chimeric have unveiled further promising results for their Car-T immune-oncology assets Rhythm Biosciences shares soar 18% on kit validation results While investors are picky, equity dollars continue to flow   There’s a long d...

The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY  Amplia up 300% in June after complete re...

Tylah Tully chats with Rhythm Biosciences (ASX:RHY) as the company undergoes a leadership transition, with outgoing Chair Otto Buttula reflecting on his tenure. Buttula paid a crucial role in overseeing RHY’s proteomic platform expansion in...

ASX surges 1pc as Iran and Israel approach ceasefire Materials and financials lead gains, adding more than 1.8pc each Energy sector drags, shedding 3.89pc as oil slumps   ASX on the rise as missiles keep firing The ASX shot up 1% today, w...

Rhythm receives reinstatement of NATA accreditation for Genetype risk assessment portfolio Genetype is a sophisticated genetic risk assessment testing platform for various diseases Reinstatement is a key milestone for securing ColoSTAT acc...

Rhythm Biosciences has expanded its original remit of bowel cancer to diagnosing other cancers early in the piece The company late last year acquired the Genetype platform from the administrators of Genetic Technologies Rhythm is developin...

Rhythm publishes peer-reviewed study validating its next-generation colorectal cancer risk assessment model Proprietary geneType assessment enhanced and cross-validated using data from nearly 400,000 individuals in UK Biobank Next generati...

Little Green Pharma reports record revenue and a return to profits Botanix raises $48 million of debt for its anti-sweating drug, Sofdra The DNA of Genetic Technologies soon will be … financial advice   Little Green Pharma’s (ASX:LGP) Eur...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

Tylah Tully chats with Rhythm Biosciences (ASX:RHY) CEO David Atkins about the company’s mission to make cancer a more treatable condition through earlier detection—starting with bowel cancer. Rhythm is developing ColoSTAT, a groundbreaking...

 Having produced more positive diagnostics results, Proteomics plans to launch its Promarker Endo device locally this year Immutep posts more positive trial results, this time for soft tissue sarcoma Broker values EBR Systems share price a...

  Rhythm successfully completes verification and validation of second-generation ColoSTAT beta assay kits Validation confirms required performance for commercialisation of simple blood test to detect bowel cancer in symptomatic patients Co...

The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR...

The S&P/ASX 200 Health Care Index fell 7.66% in February with the S&P/ASX 200 down 3.79% Morgans healthcare analyst Iain Wilkie said several factors caused investor jitters in February including job cuts to US FDA  Pacific Edge was...

Surgical probe steriliser Nanosonics flags robust December half numbers The biotech quarterlies are tricking in – and there’s mixed news Paradigm shares are worth twice as much as their current price, says Pitt Street Partners   Nanosonic...

The S&P/ASX 200 Health Care Index fell 1.85% in December but rose 7.51% overall in 2024  Mesoblast surged 52% in December after the US FDA approved its cell therapy Ryoncil for treatment of paediatric GvHD Percheron plunged 91% in Dece...

Melbourne-based bowel cancer diagnostics developer Rhythm Biosciences (ASX: RHY) has acquired the GeneType disease prediction business for $625,000 from Genetic Technologies (ASX: GTG), which entered administration last month after falling...

Rhythm Biosciences reports it has attained all key milestones for 2024 Company receives delivery of second generation ColoSTAT beta release candidate multiplex kits Rhythm has a market-entry roadmap for second generation ColoSTAT Assay wit...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

Rhythm Biosciences’ new CEO Dr David Atkins is on a mission to improve early diagnosis of bowel cancer Company raises $3.5 million in a placement supported by  several  new  institutional,  professional  and  sophisticated investors Secon...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

ASX ends very modestly lower after a mixed session Newmont and Fortescue shares drop on disappointing updates WiseTech continues its slide as investors start to grumble   Aussie shares swung to a flattish close today after earlier losses...

Telix Pharmaceuticals’ brain cancer diagnostic could leapfrog over its kidney cancer assay to be its second commercialised product Rhythm Biosciences still hopes to flush the bowel cancer ‘poo test’ into history Today’s quarterly reports s...

ASX rises as banking and tech sectors lead gains Arcadium Lithium surges on potential acquisition by Rio Tinto Retail groups urge Reserve Bank to cut rates ahead of holiday sales   The ASX200 index rose by 0.7% on Monday though investors...